


AMENDMENTS TO THE CLAIMS:


This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) A compound of the formula (I):



wherein:

- X is 1) a group of the formula




wherein


- S_1 is hydrogen or halogen,
- S_2 and S_3 are independently hydrogen, alkyl (1-6C), phenyl or benzyl,
- S_4 represents two hydrogen atoms or an oxo group,
- S_5 is H or alkyl (1-4C), and
- Y is CH_2 , O or S,

and


~~or 2) a group of the formula~~



wherein S_1 has the above meaning and R is H, alkyl (1-4C), alkoxyalkyl (2-6C),
alkenyl (2-4C) or alkynyl (2-4C),
or 3) a group of the formula-




wherein S_1 has the above meaning and Z is CH_2 , O or NH,
or 4) a group of the formula-




wherein S_1 has the above meaning,

or 5) a group of the formula




wherein S_1 has the above meaning and A is O or NH, linked to the piperazine ring with position 5 or 8,

or 6) a group of the formula



wherein S_1 has the above meaning and S_6 and S_7 represent hydrogen atoms or an oxo-group,

or 7) a group of the formula



~~wherein one of the dotted lines can represent a double bond, S₄ has the above meaning, and~~

~~P, T, and Q are independently nitrogen or NH~~

~~or P and T are independently nitrogen or NH and Q is CH or CH₂~~

~~or P and Q are independently nitrogen or NH and T is CH, CH₂, C-CH₃ or CH-CH₃~~


~~or P is nitrogen or NH, T is CH or CH₂ and Q is sulphur~~

- m has the value 2 to 6;
- n has the value 0-2;
- R₅ and R₆ are independently H or alkyl (1-3C); or R₅+R₆ represent a group -(CH₂)_p wherein p has the value 3-5, and
- R₇ is alkyl (1-3C), alkoxy (1-3C), halogen or cyano; or R₆+R₇ (R₇ at position 7 of the indole group) represent a group -(CH₂)_q wherein q has the value 2-4, an enantiomer thereof, or a salt of any of the foregoing.


2. (Canceled)

3. (Previously Presented) A compound as claimed in claim 1, wherein X is the group having formula (1), wherein S₁=S₃=S₅=H, S₄=oxo and S₂=CH₃, m is 3, R₅=R₆=H, n is 0 or 1, and R₇ is 5-fluoro, an enantiomer thereof, or a salt of any of the foregoing.

4. (Previously Presented) A method for preparing a compound, an enantiomer thereof, or a salt of any of the foregoing as claimed in claim 1, comprising reacting a compound having formula (II)



under basic conditions with a compound having formula (III)



in which formulae the symbols having the meanings given in claim 1, and L is a leaving group,

to yield the compound, the enantiomer thereof, or the salt of any of the foregoing as claimed in claim 1.

5. (Previously Presented) A pharmaceutical composition comprising at least one compound as claimed in claim 1, an enantiomer thereof, or a salt of any of the foregoing and at least one auxiliary substance.
6. (Previously Presented) A method of preparing a composition as claimed in claim 5, comprising mixing the at least one compound, an enantiomer thereof, or a salt of any of the foregoing with the at least one auxiliary substance.

7. (Currently Amended) A method of treating at least one central nervous system disorder in a human or animal patient in need of such treating, comprising administering at least one compound as claimed in claim 1, an enantiomer thereof, a salt of any of the foregoing, or a combination of the foregoing to the patient in an amount effective for the treating, wherein the at least one central nervous system disorder is chosen from ~~aggression, anxiety disorders, autism, vertigo, depression, disturbances of cognition, disturbances of memory,~~ Parkinson's disease, and schizophrenia, ~~and psychotic disorders.~~
8. (Previously Presented) The method of claim 7, in which the at least one central nervous system disorder is chosen from schizophrenia.
9. (Previously Presented) A method of treating at least one central nervous system disorder in a human or animal patient in need of such treating, comprising administering at least one compound as claimed in claim 1, an enantiomer thereof, a salt of any of the foregoing, or a combination of the foregoing to the patient in an amount effective for the treating, wherein the at least one central nervous system disorder is caused by a disturbance in the dopaminergic or serotonergic systems.